India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
Taiwan Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors – which have forced the island to adopt the most rigorous international standards and build a dense web of global…
Denmark Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself once in recent memory. Faced with flatlining sales in the late 2010s, Novo transformed from a narrow diabetes specialist into…
Africa Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up to meet demand? A new report from the Access to Medicine Foundation suggests that they can, but that new market…
China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…
Singapore Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and Project Orbis. Writing in the September 2026 edition of DIA Global Forum, Sandy Chan, Sok Bee Lim, Shirley Yong, and…
China Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data gaps, supplementary studies, and the regulatory quirks that stand in the way of a drug developed in China gaining marketing…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
USA Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of the North American market, which accounts for nearly half of the company’s global revenue and a third of its workforce.…
USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Korea Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx, discusses the company’s liquid biopsy technology, AI-driven genomic analysis and ambition to build a global precision oncology platform. He outlines…
See our Cookie Privacy Policy Here
